Claritev Corporation (NYSE:CTEV) is one of the must-buy small-cap stocks to invest in. On August 6, the company delivered its second-quarter results, asserting a return to growth bolstered by value-added solutions across an expanded vertical and growing market segments.
A close-up of a healthcare professional studying a computer screen with data while consulting with a patient.
The healthcare technology company achieved a 3.5% year-over-year revenue increase, as its adjusted EBITDA margin expanded by 94 basis points. Claritev’s net loss shrank to $62.6 million compared to a net loss of $576.7 million delivered in the same quarter last year.
Claritev saw its balance sheet receive a significant boost, with free cash flow in the second quarter increasing to $36.6 million from a negative $7 million in Q2 2024. Consequently, it ended the quarter with $56.4 million in unrestricted cash and cash equivalents.
Following the robust second-quarter results, Claritev has updated its full-year outlook. It now expects full-year revenue to be flat or increase by 2% compared to 2024 revenue. It also expects an adjusted EBITDA margin of between 62.5% and 63.5%.
Claritev Corporation is a healthcare technology, data, and insights company that offers solutions for making healthcare more transparent, fair, and affordable for all.
READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.
This article is originally published at Insider Monkey.
